|
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application
This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors.
Key Benefits
ST80...
Published: 1/20/2026
Contributor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
|
|
Precision Protein Repair Platform for Missense Mutations
Application
This technology enables targeted chemical correction of missense mutations in proteins using a modular heterotrifunctional molecule platform.
Key Benefits
Restores protein function by chemically mimicking healthy amino acid side chains.
Modular toolkit allows rapid customization for diverse protein targets.
Validated across multiple...
Published: 11/12/2025
Contributor(s): Monika Raj
|
|
Gene Editing for Head and Neck Cancer Treatment
Application
Method for delivering gene-editing therapeutic in head and neck cancers.
Key Benefits
CRISPR/CAS9-based gene editing mechanism targeting novel disease-modifying gene.
Liquid nanoparticle encapsulation permitting in vivo delivery.
Market Summary
Head and neck cancers (HNC) are the 7th most common global cancer, accounting for 3%...
Published: 11/7/2025
Contributor(s): Yong Teng, Yamin Li
|
|
Anticancer Agent with N-Glycan Specificity
Application
An engineered protein for targeting disease-associated N-glycans.
Key Benefits
High affinity, pH insensitive, no cofactors required.
Applications in anticancer and antiviral therapeutics and research.
Can aid in manufacturing monoclonal antibodies with desired N-glycosylation properties.
Market Summary
Glycosylation involves post-translation...
Published: 1/20/2026
Contributor(s): Eric J. Sundberg, Diego Sastre, Maros Huliciak
|
|
Treatment for Dengue Virus (DENV) Infection
Application
Antiviral therapeutic for multiple Dengue virus serotypes.
Key Benefits
Targets conserved regions of DENV genomes, enabling efficacy across serotypes.
Mitigates lethal infections with a single lipid nanoparticle (LNP) based dose in mice.
Minimal off-target effects.
Market Summary
Despite 390+ million annual DENV infections, there...
Published: 1/20/2026
Contributor(s): Philip Santangelo, Daryll Vanover, Chiara Zurla, Lorena Carvalho de Souza Chaves
|
|
Combinatorial Therapy for Preserving Muscle Mass During Weight Loss
Application
A combinatorial therapy to preserve muscle mass during semaglutide weight loss treatment.
Key Benefits
Preserves lean mass during semaglutide treatment in preclinical mouse models.
Increases overall fat loss without affecting food/water intake during semaglutide treatment in preclinical mouse models.
Market Summary
The prevalence...
Published: 1/28/2026
Contributor(s): Todd Golde, Yong Ran, Eric Krause, Annette De Kloet, Karen Scott
|
|
Human Brain Proteins with Evidence Consistent with Causality of Alzheimer’s and Depression
Application
Research and therapeutic targets for Alzheimer’s disease, depression, and other neurological conditions mediated by protein expression in the brain.
Key Benefits
These findings can be utilized as a research tool to better understand the genetic basis of Alzheimer’s disease.
Can also be utilized to develop therapeutics for...
Published: 11/3/2025
Contributor(s): Aliza Wingo, Thomas Wingo, Yue Liu, Allan Levey, Nicholas (Nick) Seyfried, Duc Duong
|
|
Targeted Immunotherapy for KRAS-Driven Cancers
Application
Targeted immunotherapy and companion biosensing approach for cancers harboring the KRASG12V mutation.
Key Benefits
First-in-class therapeutic strategy specifically designed for KRASG12V-positive cancers.
Addresses a significant unmet need in oncology where no approved KRASG12V-targeted therapies currently exist.
Restores the body’s...
Published: 1/21/2026
Contributor(s): Haian Fu, Cong Tang, Xiulei Mo
|
|
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application
Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax.
Key Benefits
Co-therapy increases MM sensitivity to venetoclax treatment.
Identifies patients who will respond to venetoclax therapy.
Market Summary
Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 1/20/2026
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
Mitogenic Oxygenase Regulators for Drug Discovery
Applications
Can be used as a target for drug discovery, gene therapy and, to create a diagnostic tool. These applications are relevant to conditions involving inappropriate cell proliferation (e.g., cancer, atherosclerosis), angiogenesis, and tissue damage associated with inflammatory diseases.
Technical Summary
Reactive oxygen species (ROS) include...
Published: 1/28/2026
Contributor(s): John David Lambeth, Guang Cheng
|
